[Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone].
Patients with so called aggressive multiple sclerosis were treated. The course of disease is considered aggressive if there are clinical and tomographic signs of high disease activity with the frequency of exacerbations not less than 3 during 2 years. Nine patients with this course of disease were examined. They received a combined therapy including the induction phase in which immunosuppressive drugs played a key role, and a phase of supporting therapy with immunomodulators. A variant based on drugs with opposite mechanisms of action (mitoxantron and copaxon) was worked out for the most effective use of possibilities of combined therapy. Stabilization and improvement of a patient's state by 77.8%, along with a reduction of exacerbation frequency, was found.
Sazonov
D V
DV
Malkova
N A
NA
Bulatova
E V
EV
Riabukhina
O V
OV
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D000068717:Glatiramer Acetate; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D000276:Adjuvants, Immunologic; D000700:Analgesics; D010455:Peptides; D000068717:Glatiramer Acetate; D008942:Mitoxantrone